Judah Frommer
Stock Analyst at Morgan Stanley
(3.09)
# 1,679
Out of 4,874 analysts
185
Total ratings
59.7%
Success rate
5.13%
Average return
Main Sectors:
Stocks Rated by Judah Frommer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BPMC Blueprint Medicines | Maintains: Equal-Weight | $102 → $129 | $128.15 | +0.66% | 2 | Jun 5, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Overweight | $46 → $43 | $21.17 | +103.12% | 2 | May 9, 2025 | |
| ABVX ABIVAX Société Anonyme | Assumes: Equal-Weight | $12 | $7.18 | +67.13% | 1 | Mar 20, 2025 | |
| RGNX REGENXBIO | Maintains: Overweight | $22 → $24 | $8.75 | +174.29% | 2 | Mar 14, 2025 | |
| GLPG Galapagos NV | Downgrades: Underweight | $31 → $22 | $28.07 | -21.62% | 3 | Feb 14, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Underweight | $8 → $6 | $4.07 | +47.42% | 2 | Jan 13, 2025 | |
| APLS Apellis Pharmaceuticals | Initiates: Equal-Weight | $31 | $18.40 | +68.48% | 1 | Nov 21, 2024 | |
| ACLX Arcellx | Maintains: Overweight | $81 → $106 | $64.77 | +63.66% | 2 | Nov 6, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Overweight | $35 | $8.81 | +297.28% | 1 | Oct 8, 2024 | |
| MURA Mural Oncology | Initiates: Overweight | $13 | $2.47 | +426.32% | 1 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $3 | $0.72 | +315.00% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $5.69 | +602.99% | 8 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $1.21 | +974.38% | 5 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $29.83 | +0.57% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $11.84 | +94.26% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $50 | $49.55 | +0.91% | 9 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $141 | $17.23 | +718.34% | 13 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $1.34 | +873.78% | 5 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $9 | $2.25 | +300.00% | 5 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $18.45 | +19.24% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $7 | $5.03 | +39.17% | 3 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $8 | $7.38 | +8.40% | 5 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $14.79 | +211.02% | 5 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6.5 → $7 | $1.02 | +586.27% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $51 → $55 | $14.23 | +286.51% | 3 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $101.74 | -54.79% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $49 | $86.23 | -43.18% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $328 → $370 | $982.91 | -62.36% | 2 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $31 | $76.71 | -59.59% | 6 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $76 | $74.53 | +1.97% | 8 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $182 | $112.63 | +61.59% | 9 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $107 | $99.44 | +7.60% | 15 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $95 | $133.44 | -28.81% | 10 | Jul 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $21.12 | -14.77% | 1 | Jul 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $93 → $116 | $129.92 | -10.71% | 15 | Jun 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $113.49 | -66.52% | 4 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $22 | $160.44 | -86.29% | 1 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $35 | $71.28 | -50.90% | 9 | Apr 29, 2020 |
Blueprint Medicines
Jun 5, 2025
Maintains: Equal-Weight
Price Target: $102 → $129
Current: $128.15
Upside: +0.66%
Celldex Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $46 → $43
Current: $21.17
Upside: +103.12%
ABIVAX Société Anonyme
Mar 20, 2025
Assumes: Equal-Weight
Price Target: $12
Current: $7.18
Upside: +67.13%
REGENXBIO
Mar 14, 2025
Maintains: Overweight
Price Target: $22 → $24
Current: $8.75
Upside: +174.29%
Galapagos NV
Feb 14, 2025
Downgrades: Underweight
Price Target: $31 → $22
Current: $28.07
Upside: -21.62%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Underweight
Price Target: $8 → $6
Current: $4.07
Upside: +47.42%
Apellis Pharmaceuticals
Nov 21, 2024
Initiates: Equal-Weight
Price Target: $31
Current: $18.40
Upside: +68.48%
Arcellx
Nov 6, 2024
Maintains: Overweight
Price Target: $81 → $106
Current: $64.77
Upside: +63.66%
Bicara Therapeutics
Oct 8, 2024
Initiates: Overweight
Price Target: $35
Current: $8.81
Upside: +297.28%
Mural Oncology
Apr 4, 2024
Initiates: Overweight
Price Target: $13
Current: $2.47
Upside: +426.32%
Mar 7, 2024
Assumes: Equal-Weight
Price Target: $3
Current: $0.72
Upside: +315.00%
Aug 14, 2023
Reiterates: Outperform
Price Target: $40
Current: $5.69
Upside: +602.99%
Aug 9, 2023
Reiterates: Outperform
Price Target: $13
Current: $1.21
Upside: +974.38%
Aug 9, 2023
Reiterates: Outperform
Price Target: $30
Current: $29.83
Upside: +0.57%
Aug 8, 2023
Reiterates: Outperform
Price Target: $23
Current: $11.84
Upside: +94.26%
Jul 20, 2023
Reiterates: Neutral
Price Target: $50
Current: $49.55
Upside: +0.91%
Jun 23, 2023
Reiterates: Neutral
Price Target: $141
Current: $17.23
Upside: +718.34%
May 16, 2023
Reiterates: Outperform
Price Target: $13
Current: $1.34
Upside: +873.78%
May 12, 2023
Reiterates: Outperform
Price Target: $9
Current: $2.25
Upside: +300.00%
Apr 3, 2023
Maintains: Outperform
Price Target: $21 → $22
Current: $18.45
Upside: +19.24%
Mar 31, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $5.03
Upside: +39.17%
Mar 10, 2023
Downgrades: Neutral
Price Target: $11 → $8
Current: $7.38
Upside: +8.40%
Mar 7, 2023
Reiterates: Outperform
Price Target: $46
Current: $14.79
Upside: +211.02%
Mar 7, 2023
Upgrades: Neutral
Price Target: $6.5 → $7
Current: $1.02
Upside: +586.27%
Feb 28, 2023
Maintains: Outperform
Price Target: $51 → $55
Current: $14.23
Upside: +286.51%
Feb 24, 2023
Reiterates: Outperform
Price Target: $46
Current: $101.74
Upside: -54.79%
Nov 5, 2020
Maintains: Outperform
Price Target: $47 → $49
Current: $86.23
Upside: -43.18%
Oct 6, 2020
Maintains: Neutral
Price Target: $328 → $370
Current: $982.91
Upside: -62.36%
Sep 21, 2020
Maintains: Outperform
Price Target: $24 → $31
Current: $76.71
Upside: -59.59%
Sep 21, 2020
Maintains: Outperform
Price Target: $65 → $76
Current: $74.53
Upside: +1.97%
Aug 6, 2020
Assumes: Neutral
Price Target: $182
Current: $112.63
Upside: +61.59%
Aug 6, 2020
Assumes: Outperform
Price Target: $107
Current: $99.44
Upside: +7.60%
Jul 22, 2020
Maintains: Neutral
Price Target: $90 → $95
Current: $133.44
Upside: -28.81%
Jul 21, 2020
Initiates: Outperform
Price Target: $18
Current: $21.12
Upside: -14.77%
Jun 10, 2020
Maintains: Outperform
Price Target: $93 → $116
Current: $129.92
Upside: -10.71%
May 22, 2020
Maintains: Outperform
Price Target: $31 → $38
Current: $113.49
Upside: -66.52%
May 6, 2020
Maintains: Neutral
Price Target: $18 → $22
Current: $160.44
Upside: -86.29%
Apr 29, 2020
Maintains: Neutral
Price Target: $33 → $35
Current: $71.28
Upside: -50.90%